This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the scientific discussion (also part of the EPAR).
Therapeutic Indication
### Therapeutic indication Treatment of essential hypertension. Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.
Therapeutic Area (MeSH)
ATC Code
C09CA04
ATC Item
irbesartan
Pharmacotherapeutic Group
Agents acting on the renin-angiotensin system
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| irbesartan hydrochloride | N/A | irbesartan hydrochloride |
EMA Name
Ifirmasta (previously Irbesartan Krka)
Medicine Name
Ifirmasta (previously Irbesartan Krka)
Aliases
N/ANo risk management plan link.
